Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 years of age and older who meet the criteria for study enrollment.

Trial Details

NCT ID
NCT05588648
Phase
PHASE1 / PHASE2
Sponsor
MedPacto, Inc.
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Vactosertib
Locations (sample)
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Gyeonggi-do, South Korea|37.58944,126.76917
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Subjects must meet all the following inclusion criteria to be eligible for enrollment:
  • Informed Consent/Assent Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the in…
  • Age ≥12 years at the time of screening
  • Type of Subject and Disease Characteristics

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →